A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled …
A Thakur, MR Chorawala, RS Patel - Critical Reviews in Oncology …, 2023 - Elsevier
Background and objective Aflibercept; a decoy receptor for vascular endothelial growth
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA‐Compliant single‐arm Meta‐Analysis of …
P Ge, A Reyila, X Li, S Liu, Y Jiang… - Journal of Clinical …, 2022 - Wiley Online Library
What is known and Objective Aflibercept, a recombinant protein designed to suppress the
vascular endothelial growth factor (VEGF) signalling pathway, has been used in patients …
vascular endothelial growth factor (VEGF) signalling pathway, has been used in patients …
Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study
A Durbajło, M Świeżyński, B Ziemba… - Cancers, 2024 - mdpi.com
Simple Summary The VELOUR randomized phase III trial established aflibercept (an anti-
angiogenic targeting VEGF-A, VEGF-B, and placenta growth factor) combined with FOLFIRI …
angiogenic targeting VEGF-A, VEGF-B, and placenta growth factor) combined with FOLFIRI …
Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience
D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - mdpi.com
Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
C Erol, MAN Sendur, I Bilgetekin… - Journal of cancer …, 2022 - journals.lww.com
Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen
significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) …
significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
[HTML][HTML] Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of …
RP Riechelmann, V Srimuninnimit, R Bordonaro… - Clinical colorectal …, 2019 - Elsevier
Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - Wiley Online Library
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …
Safety of aflibercept in metastatic colorectal cancer: a literature review and expert perspective on clinical and real-world data
K Muro, T Salinardi, AR Singh, T Macarulla - Cancers, 2020 - mdpi.com
Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …
globally and an increasing challenge in Asian countries. Treatment options include …